BOC Translational Hub Publications by Year
Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer. Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, García-Pedrero J, Canadas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn R. Cancer Res. 2023 Jul 14:CAN-23-1711. doi: 10.1158/0008-5472.CAN-23-1711. Online ahead of print. [PubMed]
Intraoperative Pathology Assessment May Lead to Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer Patients Undergoing Upfront Mastectomy. Pride RM, Glass CC, Nakhlis F, Laws A, Weiss AC, Bellon JR, Mittendorf EA, King TA, Kantor O. Ann Surg Oncol. 2023 Jul 12. doi: 10.1245/s10434-023-13898-2. [PubMed]
Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Cancers (Basel). 2023 Jun 21;15(13):3275. doi: 10.3390/cancers15133275. [PubMed]
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer. Villacampa G, Tung NM, Pernas S, Paré L, Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, Del Monte-Millán M, Marín-Aguilera M, Brasó-Maristany F, Waks AG, Pascual T, Martínez-Sáez O, Vivancos A, Conte PF, Guarneri V, Vittoria Dieci M, Griguolo G, Cortés J, Llombart-Cussac A, Muñoz M, Vidal M, Adamo B, Wolff AC, DeMichele A, Villagrasa P, Parker JS, Perou CM, Fernandez-Martinez A, Carey LA, Mittendorf EA, Martín M, Prat A, Tolaney SM. Ann Oncol. 2023 Jun 9:S0923-7534(23)00721-4. doi: 10.1016/j.annonc.2023.05.012. [PubMed]
Association of Surgery With Frailty Status in Older Women With Early-Stage Breast Cancer. Minami CA, Jin G, Freedman RA, Schonberg MA, King TA, Mittendorf EA. JAMA Surg. 2023 Jun 1;158(6):664-666. doi: 10.1001/jamasurg.2022.8146. [PubMed]
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. Waks AG, Ogayo ER, Paré L, Marín-Aguilera M, Brasó-Maristany F, Galván P, Castillo O, Martínez-Sáez O, Vivancos A, Villagrasa P, Villacampa G, Tarantino P, Desai N, Guerriero J, Metzger O, Tung NM, Krop IE, Parker JS, Perou CM, Prat A, Winer EP, Tolaney SM, Mittendorf EA. JAMA Oncol. 2023 Jun 1;9(6):835-840. doi: 10.1001/jamaoncol.2023.0181. [PubMed]
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ. O'Shea AE, Clifton GT, Qiao N, Heckman-Stoddard BM, Wojtowicz M, Dimond E, Bedrosian I, Weber D, Garber JE, Husband A, Pastorello R, Lee JJ, Hernandez M, Liu DD, Vornik LA, Brown PH, Alatrash G, Peoples GE, Mittendorf EA. Cancer Prev Res (Phila). 2023 Jun 1;16(6):333-341. doi: 10.1158/1940-6207.CAPR-22-0388. [PubMed]
Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial. Kantor O, King TA, Freedman RA, Mayer EL, Chavez-MacGregor M, Korde LA, Sparano JA, Mittendorf EA. JAMA Surg. 2023 Jun 1;158(6):583-591. doi: 10.1001/jamasurg.2023.0297. [PubMed]
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, Del Monte-Millán M, Massarrah T, Jerez Y, Ayala de la Peña F, García-Sáenz JÁ, Moreno F, Rodríguez-Lescure Á, Malón-Giménez D, Ballesteros García AI, Marín-Aguilera M, Galván P, Brasó-Maristany F, Waks AG, Tolaney SM, Mittendorf EA, Vivancos A, Villagrasa P, Parker JS, Perou CM, Paré L, Villacampa G, Prat A, Martín M. JAMA Oncol. 2023 Jun 1;9(6):841-846. doi: 10.1001/jamaoncol.2023.0187. [PubMed]
Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement. Trapani D, Jin Q, Block CC, Freedman RA, Lin NU, Tarantino P, Mittendorf EA, King TA, Lester SC, Brock JE, Tayob N, Bunnell CA, Tolaney SM, Burstein HJ. JCO Oncol Pract. 2023 May 16:OP2200731. doi: 10.1200/OP.22.00731. [PubMed]
Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy. Mayerhofer C, Sedrak MS, Hopkins JO, Li T, Tayob N, Faggen MG, Sinclair NF, Chen WY, Parsons HA, Mayer EL, Lange PB, Basta AS, Perilla-Glen A, Lederman RI, Wong AR, Tiwari A, McAllister SS, Mittendorf EA, Gibson CJ, Burstein HJ, Kim AS, Freedman RA, Miller PG. J Natl Cancer Inst. 2023 Apr 12:djad065. doi: 10.1093/jnci/djad065. [Pubmed]
Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. Portnow LH, Kochkodan-Self JM, Maduram A, Barrios M, Onken AM, Hong X, Mittendorf EA, Giess CS, Chikarmane SA. Radiographics. 2023 Feb;43(2):e220103. doi: 10.1148/rg.220103. [PubMed]
Metabolic abnormalities and survival among patients with non-metastatic breast cancer. Zimbalist AS, Caan BJ, Chen WY, Mittendorf EA, Dillon DAR, Quesenberry C, Cespedes Feliciano EM. BMC Cancer. 2022 Dec 29;22(1):1361. doi: 10.1186/s12885-022-10430-9. [PubMed]
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET 3rd, Attaya V, Anderson L, Mittendorf EA, Overmoyer B, Winer EP, Krop IE, Agudo J, Van Allen EM, Tolaney SM. J Immunother Cancer. 2022 Oct;10(10):e005119. doi: 10.1136/jitc-2022-005119. [PubMed]
Development of an Electronic Health Record Registry to Facilitate Collection of Commission on Cancer Metrics for Patients Undergoing Surgery for Breast Cancer. Lyu HG, Kantor O, Laws AD, McDonald J, Pham L, Dominici LS, Vincuilla J, Raut CP, Danilchuk B, Novak L, Parker T, King TA, Mittendorf EA. JCO Clin Cancer Inform. 2022 Oct;6:e2200012. doi: 10.1200/CCI.22.00012. [PubMed]
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer. Barrios CH, Saji S, Harbeck N, Zhang H, Jung KH, Patel S, Patel S, Duc AN, Liste-Hermoso M, Chui SY, Mittendorf EA. NPJ Breast Cancer. 2022 Sep 19;8(1):108. doi: 10.1038/s41523-022-00457-3. [PubMed]
Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK. Clin Cancer Res. 2022 Sep 1;28(17):3669-3676. doi: 10.1158/1078-0432.CCR-21-1278. [PubMed]
Assessment of Oncologists' Perspectives on Omission of Sentinel Lymph Node Biopsy in Women 70 Years and Older With Early-Stage Hormone Receptor-Positive Breast Cancer. Minami CA, Bryan AF, Freedman RA, Revette AC, Schonberg MA, King TA, Mittendorf EA. JAMA Netw Open. 2022 Aug 1;5(8):e2228524. doi: 10.1001/jamanetworkopen.2022.28524. [PubMed]
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, Tolaney SM. JAMA Oncol. 2022 Aug 1;8(8):1177-1183. doi: 10.1001/jamaoncol.2022.2286. [PubMed]
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. Barroso-Sousa R, Forman J, Collier K, Weber ZT, Jammihal TR, Kao KZ, Richardson ET 3rd, Keenan T, Cohen O, Manos MP, Brennick RC, Ott PA, Hodi FS, Dillon DA, Attaya V, O'Meara T, Lin NU, Van Allen EM, Rodig S, Winer EP, Mittendorf EA, Wu CJ, Wagle N, Stover DG, Shukla SA, Tolaney SM. JCO Precis Oncol. 2022 Jul;6:e2100413. doi: 10.1200/PO.21.00413. [PubMed]
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Clin Cancer Res. 2022 Jul 1;28(13):2878-2889. doi: 10.1158/1078-0432.CCR-21-3100. [PubMed]
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021. Burton EM, Amaria RN, Cascone T, Chalabi M, Gross ND, Mittendorf EA, Scolyer RA, Sharma P, Ascierto PA. J Transl Med. 2022 Jun 15;20(1):271. doi: 10.1186/s12967-022-03472-x. [PubMed]
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. Waks AG, Desai NV, Li T, Poorvu PD, Partridge AH, Sinclair N, Spring LM, Faggen M, Constantine M, Metzger O, Alberti J, Deane J, Rosenberg SM, Frank E, Tolaney SM, Krop IE, Tung NM, Tayob N, King TA, Mittendorf EA, Winer EP. NPJ Breast Cancer. 2022 May 10;8(1):63. doi: 10.1038/s41523-022-00429-7. [PubMed]
Variation in Deescalated Axillary Surgical Practices in Older Women with Early-Stage Breast Cancer. Minami CA, Jin G, Schonberg MA, Freedman RA, King TA, Mittendorf EA. Ann Surg Oncol. 2022 Apr 6:10.1245/s10434-022-11677-z. doi: 10.1245/s10434-022-11677-z. [PubMed]
Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review. Tarantino P, Curigliano G, Parsons HA, Lin NU, Krop I, Mittendorf EA, Waks A, Winer EP, Tolaney SM. JAMA Oncol. 2022 Apr 1;8(4):629-635. doi: 10.1001/jamaoncol.2021.6597. [PubMed]
Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease. Mittendorf EA, Burgers F, Haanen J, Cascone T. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-15. doi: 10.1200/EDBK_349411. [PubMed]
Race and Site of Care Impact Treatment Delays in Older Women with Non-Metastatic Breast Cancer. Song JH, Kantor O, Mittendorf EA, King TA, Minami CA. Ann Surg Oncol. 2022 Mar 30. doi: 10.1245/s10434-022-11543-y. [PubMed]
Immunotherapy for early triple negative breast cancer: research agenda for the next decade. Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, Andrè F, Curigliano G. NPJ Breast Cancer. 2022 Feb 18;8(1):23. doi: 10.1038/s41523-022-00386-1. [PubMed]
Metabolic abnormalities and survival among patients with non-metastatic breast cancer. Zimbalist AS, Caan BJ, Chen WY, Mittendorf EA, Dillon DAR, Quesenberry C, Cespedes Feliciano EM. BMC Cancer. 2022 Dec 29;22(1):1361. doi: 10.1186/s12885-022-10430-9. [PubMed]
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET 3rd, Attaya V, Anderson L, Mittendorf EA, Overmoyer B, Winer EP, Krop IE, Agudo J, Van Allen EM, Tolaney SM. J Immunother Cancer. 2022 Oct;10(10):e005119. doi: 10.1136/jitc-2022-005119. [PubMed]
Development of an Electronic Health Record Registry to Facilitate Collection of Commission on Cancer Metrics for Patients Undergoing Surgery for Breast Cancer. Lyu HG, Kantor O, Laws AD, McDonald J, Pham L, Dominici LS, Vincuilla J, Raut CP, Danilchuk B, Novak L, Parker T, King TA, Mittendorf EA. JCO Clin Cancer Inform. 2022 Oct;6:e2200012. doi: 10.1200/CCI.22.00012. [PubMed]
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer. Barrios CH, Saji S, Harbeck N, Zhang H, Jung KH, Patel S, Patel S, Duc AN, Liste-Hermoso M, Chui SY, Mittendorf EA. NPJ Breast Cancer. 2022 Sep 19;8(1):108. doi: 10.1038/s41523-022-00457-3. [PubMed]
Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JK. Clin Cancer Res. 2022 Sep 1;28(17):3669-3676. doi: 10.1158/1078-0432.CCR-21-1278. [PubMed]
Assessment of Oncologists' Perspectives on Omission of Sentinel Lymph Node Biopsy in Women 70 Years and Older With Early-Stage Hormone Receptor-Positive Breast Cancer. Minami CA, Bryan AF, Freedman RA, Revette AC, Schonberg MA, King TA, Mittendorf EA. JAMA Netw Open. 2022 Aug 1;5(8):e2228524. doi: 10.1001/jamanetworkopen.2022.28524. [PubMed]
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, Parker T, Tyekucheva S, Li T, Lin NU, Hughes ME, Weiss AC, King TA, Mittendorf EA, Curigliano G, Tolaney SM. JAMA Oncol. 2022 Aug 1;8(8):1177-1183. doi: 10.1001/jamaoncol.2022.2286. [PubMed]
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. Barroso-Sousa R, Forman J, Collier K, Weber ZT, Jammihal TR, Kao KZ, Richardson ET 3rd, Keenan T, Cohen O, Manos MP, Brennick RC, Ott PA, Hodi FS, Dillon DA, Attaya V, O'Meara T, Lin NU, Van Allen EM, Rodig S, Winer EP, Mittendorf EA, Wu CJ, Wagle N, Stover DG, Shukla SA, Tolaney SM. JCO Precis Oncol. 2022 Jul;6:e2100413. doi: 10.1200/PO.21.00413. [PubMed]
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Clin Cancer Res. 2022 Jul 1;28(13):2878-2889. doi: 10.1158/1078-0432.CCR-21-3100. [PubMed]
Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021. Burton EM, Amaria RN, Cascone T, Chalabi M, Gross ND, Mittendorf EA, Scolyer RA, Sharma P, Ascierto PA. J Transl Med. 2022 Jun 15;20(1):271. doi: 10.1186/s12967-022-03472-x. [PubMed]
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. Waks AG, Desai NV, Li T, Poorvu PD, Partridge AH, Sinclair N, Spring LM, Faggen M, Constantine M, Metzger O, Alberti J, Deane J, Rosenberg SM, Frank E, Tolaney SM, Krop IE, Tung NM, Tayob N, King TA, Mittendorf EA, Winer EP. NPJ Breast Cancer. 2022 May 10;8(1):63. doi: 10.1038/s41523-022-00429-7. [PubMed]
Variation in Deescalated Axillary Surgical Practices in Older Women with Early-Stage Breast Cancer. Minami CA, Jin G, Schonberg MA, Freedman RA, King TA, Mittendorf EA. Ann Surg Oncol. 2022 Apr 6:10.1245/s10434-022-11677-z. doi: 10.1245/s10434-022-11677-z. [PubMed]
Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review. Tarantino P, Curigliano G, Parsons HA, Lin NU, Krop I, Mittendorf EA, Waks A, Winer EP, Tolaney SM. JAMA Oncol. 2022 Apr 1;8(4):629-635. doi: 10.1001/jamaoncol.2021.6597. [PubMed]
Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease. Mittendorf EA, Burgers F, Haanen J, Cascone T. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-15. doi: 10.1200/EDBK_349411. [PubMed]
Race and Site of Care Impact Treatment Delays in Older Women with Non-Metastatic Breast Cancer. Song JH, Kantor O, Mittendorf EA, King TA, Minami CA. Ann Surg Oncol. 2022 Mar 30. doi: 10.1245/s10434-022-11543-y. [PubMed]
Immunotherapy for early triple negative breast cancer: research agenda for the next decade. Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, Andrè F, Curigliano G. NPJ Breast Cancer. 2022 Feb 18;8(1):23. doi: 10.1038/s41523-022-00386-1. [PubMed]
Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. Singh P, Scoggins ME, Sahin AA, Hwang RF, Kuerer HM, Caudle AS, Mittendorf EA, Thompson AM, Bedrosian I, Teshome M, DeSnyder SM, Meric-Bernstam F, Hunt KK. Ann Surg Open. 2020 Dec;1(2):e008. doi: 10.1097/as9.0000000000000008. [PubMed]
Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, Yee C, Lizée G. Nat Commun. 2020 Oct 21;11(1):5332. doi: 10.1038/s41467-020-19141-w. [PubMed]
Strategies to Optimize Axillary Surgery in Patients With Breast Cancer Receiving Neoadjuvant Endocrine Therapy. Weiss A, Mittendorf EA, King TA. Oncology (Williston Park). 2020 Oct 9;34(10):397-404. doi: 10.46883/ONC.2020.3410.0397. [PubMed]
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET 3rd, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE. JAMA Oncol. 2020 Oct 1;6(10):1598-1605. doi: 10.1001/jamaoncol.2020.3524. [PubMed]
Current Landscape of Immunotherapy in Breast Cancer: A Review. Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA. JAMA Oncol. 2019 Aug 1;5(8):1205-1214. doi: 10.1001/jamaoncol.2018.7147. [PubMed]
Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer. Hartl CA, Bertschi A, Puerto RB, Andresen C, Cheney EM, Mittendorf EA, Guerriero JL, Goldberg MS. J Immunother Cancer. 2019 Jul 30;7(1):199. doi: 10.1186/s40425-019-0654-5. [PubMed]
Investigation of parameters that determine Nano-DC vaccine transport. Zhang J, Mai J, Li F, Shen J, Zhang G, Li J, Hinkle LE, Lin D, Liu X, Li Z, Wang RF, Mittendorf EA, Ferrari M, Shen H. Biomed Microdevices. 2019 Apr 4;21(2):39. doi: 10.1007/s10544-019-0397-6. [PubMed]
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM. Ann Oncol. 2019 Apr 1;30(4):575-581. doi: 10.1093/annonc/mdz047. [PubMed]
Sceneay J, Goreczny GJ, Wilson K, Morrow S, DeCristo MJ, Ubellacker JM, Qin Y, Laszewski T, Stover DG, Barrera V, Hutchinson JN, Freedman RA, Mittendorf EA, McAllister SS. Interferon Signaling is Diminished with Age and is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. Cancer Discov. 2019 Jun 19. pii: CD-18-1454. doi: 10.1158/2159-8290.CD-18-1454. [PubMed]
Weiss A, King TA, Hunt KK, Mittendorf EA. Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence. Surg Clin North Am. 2018 Aug;98(4):687-702. Review. [Pubmed]
Valachis A, Mamounas EP, Mittendorf EA, Hayashi N, Ishitobi M, Natoli C, Fitzal F, Rubio IT, Tiezzi DG, Shin HC, Anderson SJ, Hunt KK, Matsuda N, Ohsumi S, Totomi A, Nilsson C. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. Cancer. 2018 Jul 15;124(14):2923-2930. [Pubmed]
Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 Jul 10. pii: S1526-8209(18)30009-0. [Pubmed]
Armer JM, Ballman KV, McCall L, Armer NC, Sun Y, Udmuangpia T, Hunt KK, Mittendorf EA, Byrd DR, Julian TB, Boughey JC. Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy. Support Care Cancer. 2018 Jul 6. [Pubmed]
Vreeland TJ, Litton JK, Qiao N, Philips AV, Alatrash G, Hale DF, Jackson DO, Peace KM, Greene JM, Berry JS, Clifton GT, Peoples GE, Mittendorf EA. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response. Clin Immunol. 2018 Jul;192:6-13. [Pubmed]
Tevis SE, Neuman HB, Mittendorf EA, Kuerer HM, Bedrosian I, DeSnyder SM, Thompson AM, Black DM, Scoggins ME, Sahin AA, Hunt KK, Caudle AS. Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins. Ann Surg Oncol. 2018 Jun 26. doi: 10.1245/s10434-018-6607-2. [Pubmed]
Stecklein SR, Park M, Liu DD, Valle Goffin JJ, Caudle AS, Mittendorf EA,Barcenas CH, Mougalian S, Woodward WA, Valero V, Sahin AA, Yang WT, Shaitelman SF. Long-Term Impact of Regional Nodal Irradiation in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Int J Radiat Oncol Biol Phys. 2018 Jun 18. pii: S0360-3016(18)31007-1. [Pubmed]
Weiss A, Chavez-MacGregor M, Lichtensztajn DY, Yi M, Tadros A, Hortobagyi GN, Giordano SH, Hunt KK, Mittendorf EA. Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. JAMA Oncol. 2018 Feb 1;4(2):203-209. [Pubmed]
Chavez-MacGregor M, Mittendorf EA. Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions. Lancet Oncol. 2017 Dec;18(12):1568-1569. [Pubmed]